Trends in endocrine therapy prescription and survival in patients with non-metastatic hormone receptor positive breast cancer treated with endocrine therapy: A population based-study.

Date publication

juin 2021

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles , Dr DABAKUYO-YONLI Sandrine , Dr LADOIRE Sylvain , Pr MAYNADIE Marc , Dr BILLA Oumar , Dr DESMOULINS Isabelle , Dr MAMGUEM KAMGA Ariane

Tous les auteurs :
Mamguem Kamga A, Billa O, Ladoire S, Poillot ML, Jolimoy G, Roignot P, Coutant C, Desmoulins I, Maynadie M, Dabakuyo-Yonli TS

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34174766

Résumé

To identify prognostic factors of invasive-disease free survival (iDFS) in women with non-metastatic hormone receptor positive (HR+) breast cancer (BC) in daily routine practice.

Mots clés

Breast cancer, Endocrine therapy, Hormone receptor positive, Invasive disease-free survival, Non-metastatic cancer

Référence

Breast. 2021 Jun 11;59:79-86